Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit in hematologic malignancies and are being evaluated in clinical trials for solid tumors. Although the short-term complicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Steffin, David H. M., Muhsen, Ibrahim N., Hill, LaQuisa C., Ramos, Carlos A., Ahmed, Nabil, Hegde, Meenakshi, Wang, Tao, Wu, Mengfen, Gottschalk, Stephen, Whittle, Sarah B., Lulla, Premal D., Mamonkin, Maksim, Omer, Bilal, Rouce, Rayne H., Heczey, Andras, Metelitsa, Leonid S., Grilley, Bambi J., Robertson, Catherine, Torrano, Virginia, Lapteva, Natalia, Gee, Adrian P., Rooney, Cliona M., Brenner, Malcolm K., Heslop, Helen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346960/
https://www.ncbi.nlm.nih.gov/pubmed/35325065
http://dx.doi.org/10.1182/blood.2022015728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346960/
https://www.ncbi.nlm.nih.gov/pubmed/35325065
http://dx.doi.org/10.1182/blood.2022015728

Ejemplares similares